The initial success of the copyright undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. While early earnings were significant, the cessation of patents and the appearance of cheaper alternatives have diminished market share. Therefore, a thorough evaluati